Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-23T03:41:36.408Z Has data issue: false hasContentIssue false
  • English
  • Français

Lack of Increased Colonization with Vancomycin-Resistant Enterococci during Preferential Use of Vancomycin for Treatment during an Outbreak of Healthcare-Associated Clostridium difficile Infection

Published online by Cambridge University Press:  02 January 2015

Mark Miller ,
Lisa Bernard ,
Melissa Thompson ,
Daniel Grima  and
Jocelyne Pepin
Mark Miller
Affiliation:
Jewish General Hospital, Montreal, Quebec, Canada
Lisa Bernard*
Affiliation:
Cornerstone Research Group, Burlington, Ontario, Canada
Melissa Thompson
Affiliation:
Cornerstone Research Group, Burlington, Ontario, Canada
Daniel Grima
Affiliation:
Cornerstone Research Group, Burlington, Ontario, Canada
Jocelyne Pepin
Affiliation:
Jewish General Hospital, Montreal, Quebec, Canada
*
Cornerstone Research Group, Suite 204, 3228 South Service Road, Burlington, Ontario L7N 3H8, Canada ([email protected])
Get access Rights & Permissions [Opens in a new window]

Extract

Objective.

To assess whether use of oral vancomycin for treatment during an outbreak of Clostridium difficile infection (CDI) was associated with increased rates of colonization with vancomycin-resistant enterococci (VRE)..

Design.

A retrospective analysis of hospital databases.

Setting.

The Jewish General Hospital in Montreal, Quebec, Canada.

Methods.

We collected data regarding VRE colonization and CDI from November 1, 2000, through September 30, 2007, during which policies of preferential oral metronidazole or vancomycin treatment were implemented to control an outbreak of CDI. Four periods were considered: period 1, the preoutbreak period when metronidazole was used; period 2, the CDI outbreak period when metronidazole was used; period 3, the postoutbreak period when vancomycin was used; and period 4, the postoutbreak period when metronidazole was used.

Results.

A total of 2,412 cases of CDI and 425 cases of VRE colonization were identified. The rate of CDI increased significantly during period 2 and decreased to preoutbreak levels during period 3. The rate of VRE also increased during period 2 and decreased during the first 18 months of period 3. A clonal outbreak of cases of VRE (VanA) colonization was observed toward the end of period 3 and into period 4. Excluding the period of the clonal outbreak, there was a strong correlation between the number of cases of CDI and VRE colonization (r = 0.736; P = .001) and a negative association between VRE colonization and vancomycin use (r = —0.765; P = .04).

Conclusions.

Increased vancomycin use was not associated with an increase in VRE colonization over a 2-year period. Restriction of vancomycin use during CDI outbreaks because of the fear of increasing VRE colonization may not be warranted.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 31 , Issue 7 , July 2010 , pp. 710 - 715
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Loo, VG, Poirier, L, Miller, M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353(23): 2442–2449.Google Scholar
2. Pépin, J, Valiquette, L, Alary, ME, et al. Clostridium diffiále-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171(5): 466–472.Google Scholar
3.Bonten, MJ, Willems, R, Weinstein, RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001; 1(5):314–325.Google Scholar
4.Shin, JW, Yong, D, Kim, MS, et al. Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. J Infect Chemother 2003;9(1): 62–67.Google Scholar
5.Moreno, A, del Rio, A, Pereda, D, et al. Vancomycin-resistant Enterococcus faecium during a nosocomial outbreak of Clostridium difficile diarrhea. Int J Antimicrob Agents 2007;29(suppl 2):S165. Abstract P687.Google Scholar
6.Poutanen, SM, Simor, S. Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171(1):51–58.Google Scholar
7.Ballard, SA, Grabsch, EA, Johnson, PD, Grayson, ML. Comparison of three PCR primer sets for identification of vanB gene carriage in feces and correlation with carriage of vancomycin-resistant enterococci: interference by vanB-containing anaerobic bacilli. Antimicrob Agents Chemother 2005; 49(1):77–81.Google Scholar
8.Mak, A, Miller, M, Chong, G, Monczak, Y. Comparison of PCR and culture for screening of vancomycin-resistant enterococci: highly disparate results for VanA and VanB. J Clin Microbiol 2009;47(12): 4136–4137.Google Scholar
9.Al-Nassir, W, Sethi, AK, Li, Y, Pultz, MJ, Riggs, MM, Donskey, CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008;52(7): 2403–2406.Google Scholar
10.Zar, FA, Bakkanagari, SR, Moorthi, KM, Davis, MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium diffcile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45(3): 302–307.Google Scholar
11.Louie, TJ, Gerson, M, Grimard, D, et al. Results of a phase III study comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2007. Abstract K425a.Google Scholar
12.Teasley, DG, Gerding, DN, Olson, MM, et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983;2(8358): 1043–1046.Google Scholar
13.Wenisch, C, Parschalk, B, Hasenhundl, M, Hirschl, AM, Graninger, W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium diffiále-assoáated diarrhea. Clin Infect Dis 1996;22(5): 813–818.Google Scholar
14.Gerding, DN. Metronidazole for Clostridium difficile-associated disease: is it okay for mom? Clin Infect Dis 2005;40(11): 1598–1600.Google Scholar